Toth Financial Advisory’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
CAM
GAA
WETS
FFA
VFA
GI
VCM
PP
CI
HPBT
Toth Financial Advisory's CRSP Position: Q3 2026 in Review
Toth Financial Advisory held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 40 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #784.
Toth Financial Advisory first reported a position in CRSP in Q1 2018 and has held it in 23 quarters since. The position peaked at $9K in Q2 2021. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Toth Financial Advisory held 40 shares of CRISPR Therapeutics worth $2.21K as of Q3 2026.
- Toth Financial Advisory left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Toth Financial Advisory's portfolio in Q3 2026, its #784 holding.
- Toth Financial Advisory first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 23 quarters since.
- Toth Financial Advisory's CRISPR Therapeutics position peaked at $9K in Q2 2021.
- 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Toth Financial Advisory's 13F filing for Q3 2026, filed 8 Oct 2026.